Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release Breastfeeding
There are high number of clear evidence that breastfeeding provides best nutrition that you can give to your baby. It is also evident that lactation is good for mothers health as well. Evolution has designed breastfeeding in a way that it caters all nutritional need of your child. However modern medicine is quite new for evolution, that is why mothers body is not well prepared to filter unnecessary chemical found in medicines. It becomes a necessity to figure out which drug is safe and which drug is dangerous for your newborn while nursing. In this article we will understand function of Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release and its suitability with breastfeeding.

What is Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release used for?


SEROQUEL XR is an atypical antipsychotic indicated for the treatment of: •Schizophrenia (1.1) •Bipolar I disorder, manic or mixed episodes (1.2) •Bipolar disorder, depressive episodes (1.2) •Major depressive disorder, adjunctive therapy with antidepressants (1.3) 1.1 Schizophrenia SEROQUEL XR is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL XR in schizophrenia was established in one 6-week and one maintenance trial in adults with schizophrenia. Efficacy was supported by three 6-week trials in adults with schizophrenia and one 6-week trial in adolescents with schizophrenia (13-17 years) treated with SEROQUEL [see Clinical Studies (14.1)]. 1.2 Bipolar Disorder SEROQUEL XR is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. The efficacy of SEROQUEL XR in manic or mixed episodes of bipolar I disorder was established in one 3-week trial in adults with manic or mixed episodes associated with bipolar I disorder. Efficacy was supported by two 12-week monotherapy trials and one 3-week adjunctive trial in adults with manic episodes associated with bipolar I disorder as well as one 3-week monotherapy trial in children and adolescents (10 – 17 years) with manic episodes associated with bipolar I disorder treated with SEROQUEL [see Clinical Studies (14.2)]. SEROQUEL XR is indicated for the acute treatment of depressive episodes associated with bipolar disorder. The efficacy of SEROQUEL XR was established in one 8-week trial in adults with bipolar I or II disorder and supported by two 8-week trials in adults with bipolar I or II disorder treated with SEROQUEL [see Clinical Studies (14.2)]. SEROQUEL XR is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was extrapolated from two maintenance trials in adults with bipolar I disorder treated with SEROQUEL. The effectiveness of monotherapy for the maintenance treatment of bipolar I disorder has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14.2)]. 1.3 Adjunctive Treatment of Major Depressive Disorder (MDD) SEROQUEL XR is indicated for use as adjunctive therapy to antidepressants for the treatment of MDD. The efficacy of SEROQUEL XR as adjunctive therapy to antidepressants in MDD was established in two 6-week trials in adults with MDD who had an inadequate response to antidepressant treatment [see Clinical Studies (14.3)]. 1.4 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.

Is Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release safe to use while breastfeeding? Can it interfere with growth and development of my kid?

Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release safe for breastfeeding
As per our analysis Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release contains only one ingredient and that is Quetiapine. We have analyzed Quetiapine and it seems to be safe to use Quetiapine while breastfeeding, that means usage of Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release shall be safe while breastfeeding. Below you can check more details of Quetiapine usage in breastfeeding. We recommend you to go through provided detailed analysis as below take decision accordingly.

Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers SEROQUEL XR was excreted into human milk. Because of the potential for serious adverse reactions in nursing infants from SEROQUEL XR, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother’s health. In published case reports, the level of quetiapine in breast milk ranged from undetectable to 170 μg/L. The estimated infant dose ranged from 0.09% to 0.43% of the weight-adjusted maternal dose. Based on a limited number (N=8) of mother/infant pairs, calculated infant daily doses range from less than 0.01 mg/kg (at a maternal daily dose up to 100 mg quetiapine) to 0.1 mg/kg (at a maternal daily dose of 400 mg).

Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release Breastfeeding Analsys


Quetiapine while Breastfeeding

Safe

CAS Number: 111974-72-2

It is excreted into breast milk in clinically significant amount. Clinical or development problems in infants whose mothers were treated have not been observed, whether at the short or long term.Very low plasma-levels in these infants were found. Galactorrhea may occur with or without an increased of Prolactin.


Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release Breastfeeding Analsys - 2


Quetiapine while Breastfeeding

CAS Number: 111974-69-7

Maternal quetiapine doses of up to 400 mg daily produce low levels in milk. Limited long-term follow-up of infants exposed to quetiapine indicates that infants generally developed normally. Systematic reviews of second-generation antipsychotics concluded that quetiapine seemed to be the first- or second-choice agent during breastfeeding.[1][2] Monitor the infant for drowsiness and developmental milestones, especially if other antipsychotics are used concurrently.



What should I do if I am breastfeeding mother and I am already exposed to Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release?

Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release is safe in breastfeeding and should not create any health problem for your baby but in case you feel any health issue associated with Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release you should contact your doctor or health care provider. Be it pregnancy or lactation you shall keep your doctor informed.


My health care provider has asked me to use Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release, what to do?

Usage of Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release is safe for nursing mothers and baby, No worries.


If I am using Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release, will my baby need extra monitoring?

No


Who can I talk to if I have questions about usage of Seroquel Xr | Quetiapine Fumarate Tablet, Extended Release in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week